Patent cliff could create need for novel delivery tech

As blockbusters go off patent and generics companies scramble to compete, novel drug delivery tech could be the difference-maker in the marketplace, Labopharm's Shams Rustom said. Speaking at Interphex, Rustom said genericsmakers can get a leg up in the battle for off-patent profits by implementing new drug delivery methods to make a drug more convenient or bioavailable, in-PharmaTechnologist reports. With many big-time sellers losing their patents in the coming years, this could mean major opportunities for drug delivery firms, Rustom said. Report

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…